Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FLXN

Flexion Therapeutics (FLXN) Stock Price, News & Analysis

Flexion Therapeutics logo

About Flexion Therapeutics Stock (NASDAQ:FLXN)

Advanced Chart

Key Stats

Today's Range
$9.12
$9.12
50-Day Range
$9.12
$9.44
52-Week Range
$4.30
$13.66
Volume
N/A
Average Volume
1.18 million shs
Market Capitalization
$458.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

Receive FLXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FLXN Stock News Headlines

New Rule Hits in July — The Smart Money Already Moved
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
VIRI Virios Therapeutics, Inc.
Spyre Therapeutics Inc SYRE
PFIZER INC's Net Worth
See More Headlines

FLXN Stock Analysis - Frequently Asked Questions

Flexion Therapeutics, Inc. (NASDAQ:FLXN) posted its quarterly earnings data on Wednesday, May, 12th. The specialty pharmaceutical company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by $0.08. The specialty pharmaceutical company earned $24.59 million during the quarter, compared to analyst estimates of $24.61 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flexion Therapeutics investors own include Regulus Therapeutics (RGLS), NVIDIA (NVDA), Gilead Sciences (GILD), Bristol-Myers Squibb (BMY), Lipocine (LPCN), Micron Technology (MU) and Viking Therapeutics (VKTX).

Company Calendar

Last Earnings
5/12/2021
Today
6/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLXN
Employees
257
Year Founded
2007

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$113.71 million
Net Margins
-100.32%
Pretax Margin
-100.32%

Debt

Sales & Book Value

Annual Sales
$85.55 million
Price / Cash Flow
N/A
Book Value
($0.34) per share
Price / Book
-26.82

Miscellaneous

Free Float
45,727,000
Market Cap
$458.93 million
Optionable
Optionable
Beta
1.53

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:FLXN) was last updated on 6/16/2025 by MarketBeat.com Staff
From Our Partners